Researchers & Healthcare Professionals

NHL & CLL Diagnosis and Treatment Update

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: September 13, 2012
CE Credit Available Until: May 16, 2014
Location: Telephone/Web
Target Audience: Oncology nurses and social workers involved in the treatment of NHL and CLL
Read: Program Slides (English) | Program Slides (Spanish) | Program Slides (Portuguese) | Transcript (English) | Transcript (Spanish)
Listen: Presentation | Q&A Session Extended Q&A |
Presentation/Q&A Session (Spanish) | Presentation/Q&A Session (Portuguese)
Access: Virtual Lecture 

Activity Purpose

To educate oncology nurses and social workers about NHL and CLL diagnosis and treatment

Educational Objectives

At the conclusion of this program, participants should be able to:

  • List signs and symptoms of indolent and aggressive NHL subtypes & CLL
  • Explain diagnosis and treatment planning for indolent and aggressive NHL subtypes & CLL
  • Identify current and emerging treatment options for patients with indolent or aggressive NHL subtypes or CLL
  • Describe the importance of clinical trials in improving patient outcomes
  • Discuss side effects management and other survivorship issues for patients
  • Explain the importance of patient-provider communications


Christopher R. Flowers, MD, MS
Associate Professor of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Questions Asked by the CLL Community

  • Are there any more clear or definitive criteria for differentiating indolent versus aggressive in chronic lymphocytic leukemia (CLL)?
  • Can people bank their own stem cells while in remission for later use? And if yes, do they last indefinitely or is there a time limit for use?
  • How effective is a mini-transplant for a CLL patient if other treatments are not working?
  • Until what age is a mini-transplant effective?
  • Are there advantages to treating a CLL patient when he/she is diagnosed instead of waiting?
  • Can you explain the phrase 'high tumor burden?'
  • For the diagnosis of diffuse large B cell lymphoma, mediastinal primary, what is the best attempt for biopsy? Is it mediastinoscopy or mediastinotomy?
  • Would you please address what oncologists are recommending in terms of exercise and diet during cancer treatment for non-Hodgkin lymphoma (NHL) and CLL?
  • Please discuss coping with lymphedema in the legs.
  • Can you talk about the difference between virus treatments being done at The University of Pennsylvania and CAL-101 and who benefits from each?
  • Are there any trials being done on the supplement called green tea, the ECGC amount, and what amounts are needed to reduce CLL effects?
  • Is there a correlation between polycythemia vera and CLL or NHL?
  • Does progression of CLL increase as the patient ages?
  • Will a bad tooth infection affect the lymph nodes?
  • Are SYK, BTK and P13IK specific to the treatment of diffuse large B-cell lymphoma?
  • What clinical trials are available for diffuse large B-cell lymphoma and what do the phases mean?
  • Is it true that years after treatment for leukemia or lymphoma, a person is at high risk for developing the other cancer? Why is this?

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society in collaboration with Abrale and Alianza Latina.

last updated on Thursday, December 13, 2012